Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

NCT05296525 is registered in ClinicalTrials.gov with Gamida Cell ltd as lead sponsor.

NCT NCT05296525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05296525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Lead sponsor
Gamida Cell ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
July 5, 2022
Completion date
April 22, 2024
Enrollment
13 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma